Jacob Mellinger

Jacob Mellinger asked about the company's pricing strategy for AMDS and NEXUS, specifically if the assumed price points ($25K for AMDS, $50K for NEXUS) are still valid given demand insensitivity, and inquired about the assumptions underpinning the 10%-14% CAGR guidance for 2026.

Answer

CEO Pat Mackin affirmed that pricing for AMDS and NEXUS is not a barrier, as these are cutting-edge, life-saving therapies with favorable reimbursement. He detailed the 2026 guidance assumptions: flat tissue revenue, mid-single-digit BioGlue growth, mid-teens On-X growth, and low twenties stent graft growth. Pat Mackin and Lance Berry noted that On-X and AMDS represent the biggest opportunities and could drive growth to the higher end of the range.

Jacob Mellingenk with Oppenheimer asked about the pricing strategy for AMDS and NEXUS, specifically if demand remains price-insensitive at assumed levels, and requested details on the assumptions underpinning the 10-14% constant currency revenue growth guidance for 2026, including how to stress test the high and low ends of the range.

Answer

Pat Mackin, CEO, stated that pricing for AMDS and NEXUS is not a barrier, given they are cutting-edge, life-saving therapies with favorable reimbursement. Pat Mackin and Lance Berry, COO and CFO, outlined the 2026 guidance assumptions: tissue flat, BioGlue mid-single-digit growth, On-X mid-teens, and stent grafts low twenties, identifying On-X and AMDS adoption rates as the primary drivers for achieving the higher end of the growth range.